Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, New York 10022
November 14, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Tonix Pharmaceuticals Holding Corp. |
Registration Statement on Form S-1 (File No. 333-234263)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4 p.m, Eastern Standard Time, on November 14, 2019, or as soon as practicable thereafter.
Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
November 14, 2019
Page 2
Very truly yours, | ||
TONIX PHARMACEUTICALS HOLDINGS CORP. | ||
By: | /s/ Bradley Saenger | |
Name: | Bradley Saenger | |
Title: | Chief Financial Officer |